April 19, 2022 -- Akron Bio has established a new current good manufacturing practice (cGMP) facility in Sarasota, FL to enhance its plasmid DNA production capabilities. The facility will reinforce Akron Bio’s place in the cell and gene therapy development space, as plasmid DNA is a major component used in the assembly of many treatments in this therapeutic field.
By using cGMP standards and safety measures, the facility will supply resources needed for the cell and gene therapy market in alignment with Akron Bio's expertise in ancillary biomaterial manufacturing.